Abnormalities in micturition: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 9: | Line 9: | ||
=== Differentiating the diseases that can cause abnormality in micturation: === | === Differentiating the diseases that can cause abnormality in micturation: === | ||
<span style="font-size:85%">'''Abbreviations:''' N= Normal, UTI= [[Urinary tract infection]], CBC= [[Complete blood count]], CT= [[Computed tomography]], IBS= [[Irritable bowel syndrome]], | <span style="font-size:85%">'''Abbreviations:''' N= Normal, UTI= [[Urinary tract infection]], CBC= [[Complete blood count]], CT= [[Computed tomography]], IBS= [[Irritable bowel syndrome]], | ||
{| | {| | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan="3" rowspan="5" |Diseases | ! colspan="3" rowspan="5" |Diseases | ||
| colspan="9 | | colspan="9" |'''Clinical manifestations''' | ||
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
| colspan="6" rowspan="2 | | colspan="6" rowspan="2" |'''Symptoms''' | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
| Line 26: | Line 24: | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
|- | |- | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! colspan=" | ! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Supra-pubic tenderness | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Supra-pubic tenderness | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin lesions | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin lesions | ||
| Line 40: | Line 37: | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysuria | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysuria | ||
!Frequency | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dribbling | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dribbling | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hesitancy | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hesitancy | ||
| Line 47: | Line 45: | ||
! rowspan="3" style="background: #DCDCDC; text-align: center;" |[[Dermatological lesions|Dermatological disorders]] | ! rowspan="3" style="background: #DCDCDC; text-align: center;" |[[Dermatological lesions|Dermatological disorders]] | ||
| style="background: #DCDCDC; text-align: center;" |[[Lichen sclerosus]] | | style="background: #DCDCDC; text-align: center;" |[[Lichen sclerosus]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 68: | Line 66: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Behcet's syndrome]] | | style="background: #DCDCDC; text-align: center;" |[[Behcet's syndrome]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 87: | Line 85: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Contact dermatitis]] | | style="background: #DCDCDC; text-align: center;" |[[Contact dermatitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 107: | Line 105: | ||
! rowspan="7" style="background: #DCDCDC; text-align: center;" |[[Infectious disease|Infectious diseases]] | ! rowspan="7" style="background: #DCDCDC; text-align: center;" |[[Infectious disease|Infectious diseases]] | ||
| style="background: #DCDCDC; text-align: center;" |[[Cystitis]] | | style="background: #DCDCDC; text-align: center;" |[[Cystitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 126: | Line 124: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Urethritis]] | | style="background: #DCDCDC; text-align: center;" |[[Urethritis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 145: | Line 143: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]] | | style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 164: | Line 162: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]] | | style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 183: | Line 181: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Cervicitis]] | | style="background: #DCDCDC; text-align: center;" |[[Cervicitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| Line 202: | Line 200: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Prostatitis]] | | style="background: #DCDCDC; text-align: center;" |[[Prostatitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 221: | Line 219: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]] | | style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| Line 244: | Line 242: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 263: | Line 261: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 283: | Line 281: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 302: | Line 300: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 322: | Line 320: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 341: | Line 339: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 361: | Line 359: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 380: | Line 378: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 398: | Line 396: | ||
! rowspan="3" style="background: #DCDCDC; text-align: center;" |[[Iatrogenic]] | ! rowspan="3" style="background: #DCDCDC; text-align: center;" |[[Iatrogenic]] | ||
| style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]] | | style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 419: | Line 417: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| Line 436: | Line 434: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Trauma]] | | style="background: #DCDCDC; text-align: center;" |[[Trauma]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Revision as of 17:16, 28 June 2018
|
Micturation Abnormalities Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Classification
Causes
Abnormalities of Micturation Differential Diagnosis
Differentiating the diseases that can cause abnormality in micturation:
Abbreviations: N= Normal, UTI= Urinary tract infection, CBC= Complete blood count, CT= Computed tomography, IBS= Irritable bowel syndrome,
| Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptoms | Physical examination | ||||||||||||||||||
| Lab Findings | Imaging | ||||||||||||||||||
| Fever | Urinary symptoms | Supra-pubic tenderness | Skin lesions | Other | CBC | Electrolytes | Urinalysis | Ultrasonography | CT scan | Other | |||||||||
| Dysuria | Frequency | Dribbling | Hesitancy | Nocturia | |||||||||||||||
| Inflammatory | Dermatological disorders | Lichen sclerosus | – | + | – | + | – | – | Lichenified plaques | – | N | N | often shows UTI in women | N | N | N | Biopsy | Associated with:[1] | |
| Behcet's syndrome | – | + | + | - | + | + | - | ||||||||||||
| Contact dermatitis | - | - | + | - | - | ||||||||||||||
| Infectious diseases | Cystitis | + | +/- | + | - | + | |||||||||||||
| Urethritis | + | - | + | - | +/- | ||||||||||||||
| Pyelonephritis | + | - | + | - | +/- | ||||||||||||||
| Vulvovaginitis | + | + | + | - | - | ||||||||||||||
| Cervicitis | + | +/- | - | - | + | ||||||||||||||
| Prostatitis | +/- | + | + | + | + | ||||||||||||||
| Epididymoorchitis | +/- | + | + | ||||||||||||||||
| Non-inflammatory | Anatomic | Urethral stricture | |||||||||||||||||
| Benign prostatic hyperplasia (BPH) | + | ||||||||||||||||||
| Drug | Spermicides | ||||||||||||||||||
| Cyclophosphamide | |||||||||||||||||||
| Endocrine disorders | Atrophic vaginitis | ||||||||||||||||||
| Endometriosis | |||||||||||||||||||
| Malignancy | Bladder cancer | ||||||||||||||||||
| Vulvovaginal cancer | |||||||||||||||||||
| Iatrogenic | Genitourinary instrumentation | + | |||||||||||||||||
| Pelvic irradiation | |||||||||||||||||||
| Trauma | ± | ||||||||||||||||||
References
- ↑ Ventolini G, Patel R, Vasquez R (2015). "Lichen sclerosus: a potpourri of misdiagnosed cases based on atypical clinical presentations". Int J Womens Health. 7: 511–5. doi:10.2147/IJWH.S82879. PMC 4431497. PMID 26056492.